OSSTEC raised £2.5 million (~USD $3.2 million) in funding. The round was led by specialist DeepTech VC Empirical Ventures with participation from Oxford Innovation Finance, SFC Capital, Embryo Ventures and Mishcon de Reya, and, due to increased interest, remains open for further investment.
This latest funding round allows OSSTEC to launch in the market and scale its impact with strategic partners in the medical field.
Based on 10 years of research at Imperial College London, OSSTEC has developed patented 3D-printing technology to mimic both cartilage articulating surfaces and bone-fixing structures. Its first product can be applied in less invasive knee implants to stimulate bone growth.
Max Munford, PhD, CEO and Founder of OSSTEC, said, “This funding marks a pivotal moment for OSSTEC, enabling us to bring our groundbreaking technology to market with our team of surgeons and engage in strategic collaborations to improve patient outcomes. We are at the exciting intersection of innovative technology, delivering value for surgeons and patients and high-growth markets, all combined to help more people stay active and pain-free for longer. We’re excited to take the next steps in scaling our impact and making a meaningful difference in patients’ lives and the wider healthcare ecosystem.”
OSSTEC raised £2.5 million (~USD $3.2 million) in funding. The round was led by specialist DeepTech VC Empirical Ventures with participation from Oxford Innovation Finance, SFC Capital, Embryo Ventures and Mishcon de Reya, and, due to increased interest, remains open for further investment.
This latest funding round allows OSSTEC to launch in...
OSSTEC raised £2.5 million (~USD $3.2 million) in funding. The round was led by specialist DeepTech VC Empirical Ventures with participation from Oxford Innovation Finance, SFC Capital, Embryo Ventures and Mishcon de Reya, and, due to increased interest, remains open for further investment.
This latest funding round allows OSSTEC to launch in the market and scale its impact with strategic partners in the medical field.
Based on 10 years of research at Imperial College London, OSSTEC has developed patented 3D-printing technology to mimic both cartilage articulating surfaces and bone-fixing structures. Its first product can be applied in less invasive knee implants to stimulate bone growth.
Max Munford, PhD, CEO and Founder of OSSTEC, said, “This funding marks a pivotal moment for OSSTEC, enabling us to bring our groundbreaking technology to market with our team of surgeons and engage in strategic collaborations to improve patient outcomes. We are at the exciting intersection of innovative technology, delivering value for surgeons and patients and high-growth markets, all combined to help more people stay active and pain-free for longer. We’re excited to take the next steps in scaling our impact and making a meaningful difference in patients’ lives and the wider healthcare ecosystem.”
Copy to clipboard 
